CartiHeal Receives FDA "Breakthrough Device Designation" for the novel Agili-C Implant
Breakthrough Designation Allows Expedited Review
KFAR SABA, Israel, Oct. 12, 2020 -- (Healthcare Sales & Marketing Network) -- CartiHeal, developer of Agili-C, a proprietary implant for the treatment of cartilage lesions in arthritic and non-arthritic... Devices, Regenerative Medicine, Orthopaedic, FDA CartiHeal, Agili-C, osteoarthritis
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Arthritis | Israel Health | Marketing | Middle East Health | Orthopaedics | Osteoarthritis | Pharmaceuticals | Rheumatology